Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 4, 2016, Pages 1152-1160

  Rao, Kanchan ^a   Adams, Stuart ^a   Qasim, Waseem ^a,b   Allwood, Zoe ^a   Worth, Austen ^a,b   Silva, Juliana ^a   Lucchini, Giovanna ^a   Chiesa, Robert ^a   Veys, Paul ^a   Amrolia, Persis ^a,b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

chimerism; hematopoietic stem cell transplantation; lineage specific; Primary immunodeficiency disorder; reduced intensity

Indexed keywords

ALEMTUZUMAB; CD40 LIGAND; CYCLOSPORIN; FLUDARABINE; IMMUNOGLOBULIN; MELPHALAN; MYCOPHENOLATE MOFETIL; THYMOCYTE ANTIBODY; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ARTICLE; CD40 LIGAND DEFICIENCY; CELL LINEAGE; CELL THERAPY; CHILD; CHILDHOOD DISEASE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC GRANULOMATOUS DISEASE; COMBINED IMMUNODEFICIENCY; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; INFECTION; LIVER DISEASE; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHAGOCYTE DYSFUNCTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SEVERE COMBINED IMMUNODEFICIENCY; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOXICITY; UNRELATED DONORS; WISKOTT ALDRICH SYNDROME; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; CYTOLOGY; DISEASE FREE SURVIVAL; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; MORTALITY; NEWBORN; STANDARDS; STEM CELL; STEM CELL TRANSPLANTATION;

CELL LINEAGE; CHIMERISM; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; INFANT, NEWBORN; MELPHALAN; STEM CELL TRANSPLANTATION; STEM CELLS; VIDARABINE;

EID: 84970024628     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.01.053     Document Type: Article

References (22)

1. 1 Worth, A.J., Booth, C., Veys, P., Stem cell transplantation for primary immune deficiency. Curr Opin Hematol 20 (2013), 501–508.
2. 2 Gyurkocza, B., Sandmaier, B.M., Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 124 (2014), 344–353.
3. 3 Breuer, S., Preuner, S., Fritsch, G., Daxberger, H., Koenig, M., Poetschger, U., et al. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia 26 (2012), 509–519.
4. 4 Eapen, M., Unrelated donor transplantation: peripheral blood or bone marrow—does it matter?. Best Pract Res Clin Haematol 27 (2014), 278–282.
5. 5 Eapen, M., Horowitz, M.M., Klein, J.P., Champlin, R.E., Loberiza, F.R. Jr., Ringden, O., et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 22 (2004), 4872–4880.
6. 6 Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995), 825–828.
7. 7 Cavazzana-Calvo, M., Carlier, F., Le Deist, F., Morillon, E., Taupin, P., Gautier, D., et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 109 (2007), 4575–4581.
8. 8 Neven, B., Leroy, S., Decaluwe, H., Le Deist, F., Picard, C., Moshous, D., et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 113 (2009), 4114–4124.
9. 9 Dey, B.R., Shaffer, J., Yee, A.J., McAfee, S., Caron, M., Power, K., et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant 40 (2007), 19–27.
10. 10 Pulsipher, M.A., Levine, J.E., Hayashi, R.J., Chan, K.W., Anderson, P., Duerst, R., et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant 35 (2005), 361–367.
11. 11 Gungor, T., Teira, P., Slatter, M., Stussi, G., Stepensky, P., Moshous, D., et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 383 (2014), 436–448.
12. 12 Petersdorf, E.W., Hansen, J.A., Martin, P.J., Woolfrey, A., Malkki, M., Gooley, T., et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 345 (2001), 1794–1800.
13. 13 Morishima, Y., Sasazuki, T., Inoko, H., Juji, T., Akaza, T., Yamamoto, K., et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99 (2002), 4200–4206.
14. 14 Mattsson, J., Ringden, O., Storb, R., Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 14:suppl 1 (2008), 165–170.
15. 15 Yu, C., Seidel, K., Nash, R.A., Deeg, H.J., Sandmaier, B.M., Barsoukov, A., et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91 (1998), 2581–2587.
16. 16 Shlomchik, W.D., Couzens, M.S., Tang, C.B., McNiff, J., Robert, M.E., Liu, J., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 (1999), 412–415.
17. 17 Teshima, T., Ordemann, R., Reddy, P., Gagin, S., Liu, C., Cooke, K.R., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8 (2002), 575–581.
18. 18 Ho, V.T., Kim, H.T., Liney, D., Milford, E., Gribben, J., Cutler, C., et al. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 37 (2006), 845–850.
19. 19 Malard, F., Furst, S., Loirat, M., Chevallier, P., El-Cheikh, J., Guillaume, T., et al. Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning. Leukemia 27 (2013), 2113–2117.
20. 20 Blache, C., Chauvin, J.M., Marie-Cardine, A., Contentin, N., Pommier, P., Dedreux, I., et al. Reduced frequency of regulatory T cells in peripheral blood stem cell compared to bone marrow transplantations. Biol Blood Marrow Transplant 16 (2010), 430–434.
21. 21 Mead, A.J., Thomson, K.J., Morris, E.C., Mohamedbhai, S., Denovan, S., Orti, G., et al. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood 115 (2010), 5147–5153.
22. 22 Morton, J., Hutchins, C., Durrant, S., Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 98 (2001), 3186–3191.